| Nonobese asthma | Obese asthma | Nonobese controls | Obese controls | p-value | |
| Subjects n | 68 | 47 | 63 | 16 | |
| Age yrs | 56.7 (39.0–64.5) | 59.0 (52.1–64.6) | 58.7 (27.9–66.4) | 57.3 (34.7–65.0) | 0.671 |
| Females % | 64.7 | 61.7 | 63.5 | 56.3 | 0.933 |
| FEV1 % pred | 82.0 (67.5–92.5)+,§ | 84.0 (67.0–95.0)+ | 101.0 (94.0–115.0) | 99.0 (82.0–111.0) | <0.001 |
| FVC % pred | 96.4±17.8+ | 92.8±15.8+,§ | 109.1±12.6 | 104.4±17.3 | <0.001 |
| FEV1/FVC | 68.5 (61.5–74.5)+,§ | 72.0 (64.0–80.0)+ | 78.0 (75.0–82.0) | 76.0 (74.0–78.5) | <0.001 |
| Atopy % | 73.5+,§ | 66.0+,§ | 41.3 | 25.0 | <0.001 |
| BMI kg·m−2 | 26.1 (23.8–28.3)§ | 34.7 (33.2–39.9)+,ƒ | 25.8 (23.4–28.0)§ | 33.0 (31.0–35.0) | <0.001 |
| ICS dose# μg·day−1 | 500 (0–1000) | 1000 (0–2000)ƒ | NA | NA | 0.003 |
| ICS use % | 58.8 | 70.2 | NA | NA | 0.212 |
| ACQ Score | 0.7 (0.4–1.3) | 0.9 (0.4–1.6) | NA | NA | 0.811 |
| GINA classification % | 0.708 | ||||
| Intermittent | 32.4 | 40.4 | NA | NA | |
| Mild persistent | 13.2 | 8.5 | NA | NA | |
| Moderate persistent | 39.7 | 34.0 | NA | NA | |
| Severe persistent | 14.7 | 17.0 | NA | NA | |
| LogPD15¶ mL | 1.81 (-0.35–2.16) | 1.91 (1.53–2.51) | NA | NA | 0.104 |
Data are presented as median (interquartile range) or mean±sd, unless otherwise stated. FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; BMI: body mass index; ICS: inhaled corticosteroid; ACQ: Asthma Control Questionnaire; GINA: Global Initiative for Asthma; PD15: provocation dose of 4.5% hypertonic saline required to induce a drop in FEV1 of 15% from baseline; NA: not available. #: beclomethasone equivalents; ¶: presented as geometric median (interquartile range); +: p<0.01 versus nonobese controls; §: p<0.02 versus obese controls; ƒ: p<0.01 versus nonobese asthma.